Viewing nowHyundai Valsartan Tablets 160 milligrams (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

MFDS item code 201601689 · Approved 2016.03.30 · Insurance code 642003800
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control essential hypertension and is effective for treating heart failure patients (NYHA class II to IV) who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of death in clinically stable myocardial infarction patients with left ventricular dysfunction and systolic dysfunction. Therefore, it is useful for managing hypertension and heart failure, as well as preventing complications after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following several weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension 6) Pediatric patients: The safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm or death to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, if pregnancy is confirmed, discontinuation should occur immediately. Patients with allergies to this drug, severely impaired liver or kidney function, or women who are pregnant or breastfeeding should not take this medication. Elderly patients, those with mild liver impairment, or patients with excessively low blood pressure or heart disease should be particularly cautious when taking this medication and should start at a low dosage while monitoring their condition closely. Although this drug has blood pressure-lowering effects, it may sometimes cause side effects such as dizziness, fatigue, headache, cough, dyspepsia, and rarely, abnormalities in blood, liver, or kidney function may occur. Because there is a risk of sudden severe drops in blood pressure leading to fainting, close observation of the condition is required when starting the medication or increasing the dosage. Taking this medication with other antihypertensive drugs, diuretics, or potassium supplements may intensify side effects, so consulting a physician or pharmacist is essential. This medication may pose risks to the fetus during pregnancy, therefore it should not be taken if pregnancy is planned or if already pregnant, and it is also advisable to avoid in breastfeeding. Safety and efficacy in children and teenagers have not been established, so its use is not recommended in this population. In case of an overdose, there is a risk of hypotension, decreased consciousness, and shock, so immediate medical attention is required for proper treatment. This medication should be kept out of the reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its effectiveness.
Oval film-coated tablets that are orange with a grayish hue
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.